Review articleThe protein structure and effect of factor VIII
Section snippets
The protein structure of factor VIII
The primary structure of human FVIII was deduced from its cDNA sequence [6]. It was consistent with partial sequence analysis of tryptic peptides [7]. FVIII is synthesized as a 300 kDa precursor protein, which is a 2332-residue single-chain glycoprotein, composed of three distinct domain types in the arrangement, namely (NH2) A1–A2–B–A3–C1–C2 (COOH) [8] (see Fig. 1). Among species, amino acids are highly homologous except for their B domains. The FVIII protein is secreted as a heterodimer, a
The effect of FVIII
FVIII is a plasma glycoprotein that functions as an essential cofactor in blood coagulation [35]. FVIII binds to and circulates with vWF as an inactive precursor. It is activated by thrombin or FXa, which cleaves FVIII at Arg372, between the A1 and A2 domains; at Arg740, between the A2 and B domains; and at Arg1689, which releases the A2 peptide from the light chain [36]. In vitro, trace amounts of thrombin can markedly enhance apparent FVIII clotting activity [37] and the apparent specific
The hemophilia and mutation of protein structure in factor VIII
Quantitative or qualitative deficiencies of FVIII result in the inherited bleeding disorder hemophilia A [70]. Hemophilia A is a sex-linked disorder that results from a deficiency of functional FVIII. Deficiency of FVIII activity leads to hemophilia A, a congenital bleeding tendency of variable severity that is due to a large number of distinct FVIII gene mutations [71].
The effect of recombinant FVIII protein
Greater understanding of the structure–function relationships in the FVIII gene and protein will continue to guide development of more effective recombinant therapeutics and of gene therapy for patients with disease. The past 10 years of clinical experience have demonstrated the safety and efficacy of recombinant FVIII(rFVIII). Now, insights from our understanding of clotting factor structure and function, mechanisms, gene therapy advances and a worldwide demand for clotting factor concentrates
References (100)
- et al.
Mutations associated with hemophilia A in the 558–565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex
Blood
(2002) - et al.
Elevated plasma levels of factor VIII in women with early recurrent miscarriage
J Thromb Haemost
(2003) - et al.
Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase
Blood
(2000) - et al.
Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII
J Biol Chem
(2003) - et al.
Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII
J Biol Chem
(1997) - et al.
Residues 484–508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII
J Biol Chem
(1995) - et al.
Factor VIIIa A2 subunit residues 558–565 represent a factor IXa interactive site
J Biol Chem
(1994) - et al.
Factor IXa : factor VIIIa interaction–helix 330–338 of factor IX interacts with residues 558–565 and spatially adjacent regions of the A2 subunit of factor VIIIa
J Biol Chem
(2001) - et al.
The sequence Glu1811–Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor VIII comprises a binding site for activated factor IX
J Biol Chem
(1996) - et al.
Localization of a factor X interactive site in the A1 subunit of factor VIIIa
J Biol Chem
(1997)
Identification of the binding site for activated protein C on the light chain of factors V and VIII
J Biol Chem
A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells
J Biol Chem
Biochemical, immunological and in vivo functional characterization of B-domain-deleted factor VIII
Blood
The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor
J Thromb Haemost
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure
Blood
Structure of a factor VIII C2 domain-immunoglobulin G4k Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII
Blood
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
Blood
Antigenicity of putative phospholipid membrane-binding residues in factor VIII
Blood
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor
J Biol Chem
The factor VIII C2 domain contains the thrombin binding site responsible for thrombin-catalyzed cleavage at Arg 1689
J Biol Chem
Role of factor VIII C2 domain in factor VIII binding to factor Xa
J Biol Chem
Surface-exposed hemophilic mutations across the FVIII C2 domain have variable effects on stability and binding activities
J Biol Chem
The importance of activation of antihemophilic globulin and procaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity
Blood
Inactivation of factor VIII by activated protein C and protein S
Arch Biochem Biophys
The role of phospholipid and factor VIIIa in the activation of bovine factor X
J Biol Chem
Sites in the A2 subunit involved in the interfactor VIIIa interaction
J Biol Chem
Identification of a factor Xa-interactive site within residues 337–372 of the factor VIII heavy chain
J Biol Chem
Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa
J Biol Chem
Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain
J Biol Chem
Structural requirements for the activation of human factor VIII by thrombin
Blood
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor
J Biol Chem
von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver
Blood
Coagulation factor VIII: structure and stability
Int J Pharm
Factor VIIIa cofactor activity shows enhanced ionic strength sensitivity in the absence of phospholipid
Biochim Biophys Acta
Structural and functional characterization of platelet receptor-mediated factor VIII binding
J Biol Chem
Residues 110–126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity
J Biol Chem
Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase
J Biol Chem
Bioengineering of coagulation factor VIII for improved secretion
Blood
An immunogenic region within residues Val1670–Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor
J Biol Chem
Molecular mechanisms of mild and moderate hemophilia A
J Thromb Haemost
The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein
J Biol Chem
Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein–protein interactions within the triplicated A domains of thrombin-activated factor VIIIa
Blood
Environmental and genetic factors influencing inhibitor development
Semin Hematol
The promise and challenges of bioengineered recombinant clotting factors
J Thromb Haemost
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
J Thromb Haemost
The future of recombinant coagulation factors
J Thromb Haemost
The future of recombinant coagulation factors
J Thromb Haemost
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
J Thromb Haemost
Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII
J Thromb Haemost
In vivo neutralization of a C2 domain-specific human anti-factor VIII inhibitor by an anti-idiotypic antibody
Blood
Cited by (41)
A high efficient FVIII variant corrects bleeding in hemophilia A mouse model
2022, Biochemical and Biophysical Research CommunicationsFunctional identification of factor VIII B domain regions in hepatocyte cells
2020, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Factor VIII (FVIII) is an important cofactor for the proteolytic activation of factor X by activated factor IX in the presence of Ca2+ and phospholipids within the intrinsic pathway of blood coagulation [1–3].
Venous thromboembolism, factor VIII and chronic kidney disease
2018, Thrombosis ResearchCitation Excerpt :After FVIII is secreted by exocytosis and once in the plasma, it is stabilized by non-covalent association with vWF. This increases the half-life of vWF-bound FVIII to about 10 h [53] by preventing inactivation by activated protein C, FIXa and FXa [54,55]. Deficiency of vWF-FVIII binding as in von Willebrand disease type 2N, results in a secondary FVIII deficiency, due to more efficient clearance from the circulation.
Expression and Synthesis of Recombinant Human Coagulation Factor VIII Using a Cell-Free Expression System
2024, Journal of Babol University of Medical SciencesA frameshift deletion in F8 associated with hemophilia A in Labrador Retriever dogs
2023, Animal Genetics